- The COVID-19 vaccine developed by Sinovac Biotech Ltd does not create enough antibodies to neutralise the COVID-19 Omicron variant.
- The investigation study of 25 individuals who received the full Sinovac COVID-19 vaccines showed that none of them had antibodies in their blood serum sufficient to neutralise the Omicron variant.
Worrying Results From University Of Hong Kong Reveal Sinovac Vaccine Unable To Protect Against Omicron Variant, Public Urged To Go For Boosters
According to University of Hong Kong researchers, the COVID-19 vaccine developed by Sinovac Biotech Ltd, which is one of the most extensively used COVID-19 vaccines globally, does not create enough antibodies to neutralise the COVID-19 Omicron variant.
The results are anticipated to have a significant impact on the millions of individuals worldwide who rely on the vaccination to protect them against covid infections. A team of researchers at the University of Hong Kong stated in a statement published Dec 14 that the findings were based on the results of a study of 25 individuals who received the full Sinovac COVID-19 vaccines.
source - SCMP
The investigation showed that none of them had antibodies in their blood serum sufficient to neutralise the Omicron variant. Meanwhile, in a separate investigation involving 25 patients who received injections of RNA vaccines manufactured by Pfizer and BioNTech SE, the researchers revealed that five participants were capable of neutralising the new variant.
This is consistent with the two firms’ announcement last week that the third dose injection of the Pfizer COVID-19 vaccine is adequate to protect against the Omicron variant.
Additionally, the researchers advocated revaccinating the world’s population to combat this new strain, while noting that much remains unclear about Sinovac’s response to Omicron. Additionally, the Beijing-based corporation did not immediately respond to the results of a University of Hong Kong investigation.
The public is strongly encouraged to get a third dose as soon as feasible in light of these results.